Bringing Advanced Therapies for Parkinson's Disease to the Clinic: An Analysis of Ethical Issues

Research output: Contribution to journalReview articlepeer-review


Advanced therapies for Parkinson's disease (PD) constitute a broad range of treatments, each presenting specific ethical challenges. Some of these therapies are established and in clinical use, like device-aided therapies, and others, based on advanced therapeutic medicinal products (ATMPs), are still in early stage of clinical trials. This paper focuses on some common ethical issues arising in these two categories of advanced therapies, especially challenges arising when advanced therapies are proposed to PD patients in the form of advanced care, under a clinical trial, or, in case of ATMPs, under the 'hospital exemption' rule. The ethical issues covered here relate mainly to ensuring informed consent in these different contexts, to the stakeholder role of patient's non-professional caretakers, such as family, and to patient safety in treatments under 'hospital exemption'. To illustrate the points discussed in connection with 'hospital exemption' rule, the example of the EU has been chosen. This paper does not claim completeness of ethical issues raised by bringing advanced therapies for PD to the clinic, but rather presents examples of ethical challenges in this context.

Original languageEnglish
Pages (from-to)S147-S153
JournalJournal of Parkinson's Disease
Issue numbers2
Publication statusPublished - 2021

Subject classification (UKÄ)

  • Neurology
  • Medical Ethics

Free keywords

  • advanced therapeutic medicinal products
  • advanced therapies
  • ethics
  • Parkinson's disease


Dive into the research topics of 'Bringing Advanced Therapies for Parkinson's Disease to the Clinic: An Analysis of Ethical Issues'. Together they form a unique fingerprint.

Cite this